Medicare Has Negotiated Price Discounts for 10 Blockbuster Drugs

If you’ve ever tried to negotiate anything in Americarent, cable bills, the price of a “lightly used” treadmillyou know it can feel like arguing with a robot. But in a plot twist worthy of prime-time TV, Medicare has officially entered its bargaining era and negotiated new prices for 10 blockbuster prescription drugs.

Translation: for the first time, Medicare didn’t just politely accept the sticker price and whisper “thank you.” It brought receipts, did the math, and landed price discounts that (depending on the drug) are big enough to make a pharmacy cashier do a double-take. These negotiated prices are scheduled to kick in on January 1, 2026 for Medicare Part D.

What Happened (In Plain English)

Under the Inflation Reduction Act, Medicare can negotiate prices for certain high-spend, single-source drugs (meaning: no generic or biosimilar competition). The negotiated amounts are called Maximum Fair Prices (MFPs). The concept is simple: if Medicare is one of the biggest buyers in the country, it should be able to use that buying power like every other big buyer does.

The first round targets drugs that drive major Medicare Part D spendingmedications used for conditions like diabetes, heart failure, autoimmune diseases, and cancer. The result: Medicare announced negotiated MFPs that represent 38% to 79% discounts off 2023 list prices, depending on the drug. That range is basically “nice haircut” to “whoa, did you have a coupon code?”.

The 10 Blockbuster Drugs and Their Negotiated Discounts

Here’s the lineup. Prices below are standardized by Medicare as a 30-day supply for comparison purposes (because drug pricing is complicated enough without making everyone do unit conversions before coffee).

Quick takeaways from the table

• Biggest percentage discount: Januvia at 79% off the 2023 list price.
• Smallest percentage discount: Imbruvica at 38% offstill meaningful, but not the “drop everything and tell your group chat” kind of cut.
• High-impact everyday meds: Eliquis, Jardiance, and Xarelto are widely used and drive huge spendingso even moderate discounts can move real money.
• Specialty drug reality check: Drugs like Stelara, Enbrel, and Imbruvica are still expensive after discounts. This is progress, not magic.

How Medicare Picked These Drugs

Medicare didn’t throw darts at a pharmacy shelf. The law sets rules: selected drugs must be high-spend in Medicare and lack generic or biosimilar competition. There are also “age” requirements (how long the drug has been on the market) and exclusions for certain types of drugs.

In practice, that’s why this list includes major chronic-condition medications (diabetes, heart failure, blood clot prevention) plus a few high-cost specialty drugs for autoimmune disease and cancer. In 2023 alone, about 8.8 million Medicare Part D enrollees used at least one of these drugs, and the group represented roughly $56.2 billion in total Part D gross covered prescription drug costs.

How the “Maximum Fair Price” Negotiation Actually Works

Negotiation here is structured, formal, andsadlydoes not involve Medicare leaning across a table saying, “C’mon, buddy.” Medicare sends an initial offer, manufacturers respond with counteroffers, and both sides meet and exchange revised offers. In some cases, Medicare accepted a revised counteroffer; in others, Medicare issued a final offer that manufacturers accepted.

A key detail: the MFP is not the same as a retail pharmacy “cash price,” and it’s not automatically your exact copay. It’s a negotiated ceiling on what Medicare pays for the drug under Part D once it takes effect. Your out-of-pocket cost depends on your plan’s benefit design (copays vs. coinsurance), where you are in the benefit phases, and whether you receive subsidies.

What This Means for Medicare Part D Members (The Money Part)

Medicare estimates these negotiated prices would have reduced net spending by about $6 billion if they had applied in 2023, and projects about $1.5 billion in aggregate out-of-pocket savings for Part D enrollees in 2026 (under the standard benefit design). That’s not a rounding error; that’s “maybe you can finally replace the dishwasher that sounds like a helicopter” money.

Why you might actually feel the savings

• Coinsurance math gets less painful: If your plan uses coinsurance (a percentage of the drug’s price), a lower negotiated price can translate into a lower dollar amount at the counter.
• Some specialty drug shock may soften: For example, Medicare highlighted a scenario where a beneficiary paying 25% coinsurance for Stelara could see that coinsurance amount fall substantially when the negotiated price applies.
• Out-of-pocket caps change the game: Recent Part D redesign includes an annual out-of-pocket cap (introduced in 2025 and indexed thereafter), which can especially matter for people taking high-cost specialty drugs.

Important reality check: even after negotiation, some specialty drugs remain expensive. A 66% discount on a four-figure drug is still… a four-figure drug. The negotiation program is meant to bend the cost curve, not teleport us into a world where biologics cost the same as breath mints.

What This Means for Everyone Else (Yes, Even If You’re Not on Medicare)

Medicare is a giant buyer. When a buyer that big changes how prices are set, the ripples can spread: employer plans, commercial insurers, pharmacy benefit managers, and even manufacturers’ launch strategies may pay attention.

One estimate found millions of people with employer-sponsored insurance also use at least one of the drugs on the negotiation list. And researchers have compared Medicare’s negotiated prices to what other payers and even other countries payhighlighting how unusual U.S. pricing can be.

The Pushback: Lawsuits, Innovation Arguments, and the “Yeah, But…” Section

No blockbuster policy change is complete without blockbuster drama. Drug manufacturers and industry groups have challenged the negotiation program in court, arguing it’s unfair or unconstitutional and warning it could reduce incentives to develop new medicines. Supporters counter that the program targets drugs long on the market without competition and aims to reduce prices that have climbed dramatically over time.

The debate isn’t going away. But for patients and caregivers doing the monthly “Do we pay for meds or pay for groceries?” spreadsheet, lower negotiated prices are the kind of practical policy that can matter.

What You Should Do If You Take One of These Drugs

You don’t need to memorize policy acronyms to benefit. A few smart moves can help you capture savings (and avoid surprises) as the negotiated prices approach:

1) Review your Part D coverage every year

Formularies, tiers, copays, and prior authorization rules can change. During open enrollment, compare plans based on your exact medications and pharmacies. A negotiated MFP helps, but plan design still matters a lot.

2) Ask how your plan charges you: copay vs. coinsurance

Coinsurance is where price changes can really show up. If you pay a flat copay, savings may be less direct (though plan premiums and tiering policies can still shift).

3) Talk to your prescriber about therapeutic alternatives (without panic-switching)

Some people may have clinically appropriate alternatives (including lower-cost options) depending on their diagnosis and history. Don’t change meds just because a headline sounded excitinguse it as a reason to have a real conversation.

4) If insulin is involved, double-check your benefits

Insulin rules have changed recently in Medicare, and plan details still vary. Make sure you know what applies to your specific insulin product, your pharmacy network, and your dosing needs.

What’s Next After These 10 Drugs?

This first set of negotiated prices is the opening act. Medicare is scheduled to negotiate additional drugs in future rounds, increasing the number selected each year and eventually expanding negotiations to include certain Part B drugs (typically administered in clinical settings).

That means today’s list isn’t the final wordit’s the first proof that Medicare can negotiate and publish concrete prices, not just talk about affordability in abstract terms.

Real-World Experiences: What the Discounts May Feel Like in 2026 (And Why It Won’t Be Identical for Everyone)

Here’s the part most people actually care about: “Cool policy story. So… will I pay less?” The honest answer is often yes, but the path from a negotiated Medicare price to your receipt can run through a maze of plan rules, benefit phases, and pharmacy network fine print. Think of it like booking airfare: the plane is the same, but somehow the person in 14B paid $212 and you paid $487 because you clicked on a Tuesday.

In many households, the biggest emotional pain point isn’t the annual totalit’s the monthly spike. Specialty drugs like Stelara, Enbrel, and Imbruvica can create sticker shock early in the year before you hit a phase where cost-sharing changes. With negotiated prices, that spike may shrink. If your cost is based on a percentage (coinsurance), a lower negotiated price can reduce that “wait, is this a mortgage payment?” moment. Even when the drug remains expensive, fewer people may feel forced into delaying refills, splitting doses, or playing the risky game of “I’ll stretch it.”

For people taking high-volume “everyday” drugs like Eliquis, Jardiance, or Xarelto, the experience can be more subtlebut still meaningful. Instead of one huge bill, the benefit may show up as a steadier, slightly lower cost over the year, especially if your plan ties cost-sharing to price. And because these meds are widely used, system-level savings can be substantial even if each individual refill only drops by a modest amount. That’s the unglamorous power of public health math: a small change applied to millions of fills is still a big deal.

The insulin piece may feel the most “human” because insulin affordability is a daily reality, not an abstract budget line. Medicare’s negotiated insulin MFP is designed to lower the underlying price Medicare pays. Depending on your plan structure, you might see a more predictable payment patternand fewer “why did it jump this month?” surprises. The best move is practical: as 2026 approaches, ask your pharmacist to run a test claim (many can) and confirm what you’ll pay at that pharmacy, on that plan, for that exact insulin product. The difference between “should be cheaper” and “is cheaper” often lives in those details.

Another real-world factor: not everyone uses the standard benefit design. Low-income subsidies, employer retiree coverage, and plan-specific copay structures can dramatically change what you personally pay. That’s why two neighbors on the same street can take the same drug and have very different experiences. One may see the price cut immediately; the other may see it indirectly through plan choices, tier changes, or better protection from catastrophic spending. This isn’t a flaw as much as it’s the reality of how Part D has evolvedlayered, plan-driven, and occasionally confusing enough to deserve its own escape room.

The most useful “experience-based” advice is boringbut effective: shop your coverage, ask precise questions, and document answers. Keep a simple list of medications, doses, and preferred pharmacies. During open enrollment, compare total annual cost (premium + expected copays/coinsurance), not just premium. If a representative tells you something important (“That drug will be Tier 3 all year”), write it down with the date and name. When real money is involved, being politely persistent beats being passively optimistic.

Bottom line: negotiated Medicare drug prices are a real, measurable shift. They won’t make every prescription cheap, and they won’t hit every plan identically. But they can make the system less punishingespecially for people who’ve been paying the “because we said so” price for years.

Conclusion

Medicare’s negotiated price discounts for these 10 blockbuster drugs mark a historic change in how prescription drug costs can be managed in the U.S. The negotiated Maximum Fair Prices won’t solve every affordability problem overnightbut they do create real downward pressure on some of the most expensive and widely used medications in Medicare Part D. If you or someone you love takes one of these drugs, 2026 is a date worth circling preferably with a pen that costs less than your copay used to.